Neuroinflammation

Neuroscience Bulletin

Volumn 31, Issue 6, 2015, Pages 714-716

  Shi, Fu Dong ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; CYTOKINE; FINGOLIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR;

ALZHEIMER DISEASE; ANTIBODY RESPONSE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; DISEASE COURSE; EDITORIAL; ENCEPHALITIS; ENDOTHELIUM CELL; EXCITOTOXICITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE; MEDIATOR RELEASE; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELOOPTIC NEUROPATHY; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEWBORN SEPSIS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; TRAUMATIC BRAIN INJURY; ANIMAL; CENTRAL NERVOUS SYSTEM; IMMUNOLOGY; INFLAMMATION; PATHOLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; INFLAMMATION;

EID: 84948748947     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-015-1568-y     Document Type: Editorial

References (13)

1. Fu Y, Liu Q, Anrather J, Shi FD. Immune interventions in stroke. Nat Rev Neurol 2015, 11: 524–535.
2. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015, 14: 388–405.
3. Huang D. Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics. Neurosci Bull 2015, 31: 745–754.
4. Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013, 12: 554–562.
5. Li M, Yan Y. Experimental models of neuromyelitis optica: current status, challenges and future directions. Neurosci Bull 2015, 31: 735–744.
6. Zhou JJ, Cheng C, Qiu Z, Zhou WH, Cheng GQ. Decreased connexin 43 in astrocytes inhibits the neuroinflammatory reaction in an acute mouse model of neonatal sepsis. Neurosci Bull 2015, 31: 763–768.
7. Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ, et al. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proofof- concept study. JAMA Neurol 2014, 71: 1092–1101.
8. Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A 2014, 111: 18315–18320.
9. Zhu Z, Fu Y, Tian D, Sun N, Han W, Chang G, et al. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation 2015, 132: 1104–1112.
10. Li YJ, Chang GQ, Liu Y, Gong Y, Yang C, Wood K, et al. Fingolimod alters inflammatory mediators and vascular permeability in intracerebral hemorrhage. Neurosci Bull 2015, 31: 755–762.
11. Yan T, Chopp M, Chen J. Experimental animal models and inflammatory cellular changes in cerebral ischemic and hemorrhagic stroke. Neurosci Bull 2015, 31: 717–734.
12. Shi F D, Ljunggren HG, La Cava A, van Kaer L. Organspecific features of natural killer cells. Nat Rev Immunol 2011, 11: 658–671.
13. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015, 523: 337–341.